224 related articles for article (PubMed ID: 27038323)
1. PDE4B as a microglia target to reduce neuroinflammation.
Pearse DD; Hughes ZA
Glia; 2016 Oct; 64(10):1698-709. PubMed ID: 27038323
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
3. The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation.
Hedde JR; Hanks AN; Schmidt CJ; Hughes ZA
Brain Behav Immun; 2017 Aug; 64():285-295. PubMed ID: 28438557
[TBL] [Abstract][Full Text] [Related]
4. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation.
Avila DV; Myers SA; Zhang J; Kharebava G; McClain CJ; Kim HY; Whittemore SR; Gobejishvili L; Barve S
Neuropharmacology; 2017 Oct; 125():376-385. PubMed ID: 28807677
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of phosphodiesterase-4 subtypes involved in surgery-induced neuroinflammation and cognitive dysfunction in mice.
Wang W; Zhang XY; Feng ZG; Wang DX; Zhang H; Sui B; Zhang YY; Zhao WX; Fu Q; Xu ZP; Mi WD
Brain Res Bull; 2017 Apr; 130():274-282. PubMed ID: 28235598
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
[TBL] [Abstract][Full Text] [Related]
8. Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis.
Schepers M; Paes D; Tiane A; Rombaut B; Piccart E; van Veggel L; Gervois P; Wolfs E; Lambrichts I; Brullo C; Bruno O; Fedele E; Ricciarelli R; Ffrench-Constant C; Bechler ME; van Schaik P; Baron W; Lefevere E; Wasner K; Grünewald A; Verfaillie C; Baeten P; Broux B; Wieringa P; Hellings N; Prickaerts J; Vanmierlo T
Brain Behav Immun; 2023 Mar; 109():1-22. PubMed ID: 36584795
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphodiesterase-4 in the spinal dorsal horn ameliorates neuropathic pain via cAMP-cytokine-Cx43 signaling in mice.
Zhang FF; Wang H; Zhou YM; Yu HY; Zhang M; Du X; Wang D; Zhang F; Xu Y; Zhang JG; Zhang HT
CNS Neurosci Ther; 2022 May; 28(5):749-760. PubMed ID: 35156776
[TBL] [Abstract][Full Text] [Related]
10. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
12. Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.
Ghosh M; Garcia-Castillo D; Aguirre V; Golshani R; Atkins CM; Bramlett HM; Dietrich WD; Pearse DD
Glia; 2012 Dec; 60(12):1839-59. PubMed ID: 22865690
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury.
Xu M; Yu X; Meng X; Huang S; Zhang Y; Zhang A; Jia Z
Am J Physiol Renal Physiol; 2020 Mar; 318(3):F576-F588. PubMed ID: 31961716
[TBL] [Abstract][Full Text] [Related]
15. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
17. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
[TBL] [Abstract][Full Text] [Related]
18. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.
Srivani P; Usharani D; Jemmis ED; Sastry GN
Curr Pharm Des; 2008; 14(36):3854-72. PubMed ID: 19128237
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
